Tech Pioneers

More Good Cholesterol

Resverlogix

Calgary, Alberta
Sector: Biotechnology
Donald McCaffrey, Co-Founder and CEO
Age: 49

Resverlogix develops therapies for cardiovascular disease, cancer, and fibrotic conditions. It has created a new class of drugs that reduces the risk of cardiovascular disease by boosting the body's production of ApoA-I, the primary protein component of HDL ("good cholesterol"), which removes plaque from the arteries. Cardiovascular disease kills more people in developed nations than all cancers combined.